- X4 Pharmaceuticals Inc XFOR new dates announced from its Phase 1b study evaluating the ability of its lead clinical candidate, mavorixafor, to increase absolute neutrophil count (ANC) in patients with chronic neutropenia (CN) as monotherapy or concomitantly with injectable granulocyte colony-stimulating factor (G-CSF). .
- People with CN have lower levels of neutrophils, a type of white blood cell, for more than three months.
- 100% of study participants (n=25) responded to treatment with a single dose of 400 mg mavorixafor.
- All neutropenic participants (n=14) achieved normalized ANC values.
- Related: X4 Pharma Cessates Further Work on Oncology Programs and Seeks Partner(s).
- When evaluated as monotherapy in subjects with severe chronic neutropenia not treated with G-CSF (n=6), a single dose of mavorixafor resulted in normalized ANC levels in all subjects within 2 hours.
- When evaluating participants with moderate or severe neutropenia despite treatment with G-CSF (n=8), 100% achieved normalized ANC values.
- Mavorixafor was well tolerated in the study, all treatment-related adverse events were classified as minor, and no treatment-related serious adverse events were reported.
- Price promotion: XFOR shares are up 14.39% to $1.02 on the latest check Tuesday.
© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
[ad_2]
Source story
